1 / 10

Wednesday July 11. 2012 Cheryl Jennings, Bria Dawson, Even Skjervold , & Kali Luffy

Periorbital Drug Delivery. Wednesday July 11. 2012 Cheryl Jennings, Bria Dawson, Even Skjervold , & Kali Luffy. Overview. Continuing drug release study with FDA Started drug release study with Valganciclovir & Ganciclovir Visited the HIV clinic and met with Dr. Rupesh Agrawal

tallys
Download Presentation

Wednesday July 11. 2012 Cheryl Jennings, Bria Dawson, Even Skjervold , & Kali Luffy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Periorbital Drug Delivery Wednesday July 11. 2012 Cheryl Jennings, Bria Dawson, Even Skjervold, & Kali Luffy

  2. Overview • Continuing drug release study with FDA • Started drug release study with Valganciclovir & Ganciclovir • Visited the HIV clinic and met with Dr. RupeshAgrawal • Continued trying to find a common solvent

  3. Brief Drug Release Procedure • Remove 20uL from master plate into read plate with 180uL of 0.1M NaOH (for fluorescence) • Remove rest of PBS tween 80 from master plate and replace with 200uL of new PBS tween 80 • Put master plates back in oven to incubate • For dilution, we removed 20uL from the read plate and 180uL of 0.1M NaOH • Fluorescence readings of both read plates were performed and analyzed

  4. Example 96 Well Plates with Films

  5. FDA Release Study • Have had to 10X dilute every time point (we are currently on day 16) • This concludes that the amount of drug in the film is too great and could be decreased in future studies • Possible sources of error • Reusing well plates • Working under lighted conditions • Will continue this study until day 30 • Then analyze on “Master Sheet”

  6. Valganciclovir & Ganciclovir Release Study • Started the drug release study using 180 ulHCl buffer (pH 1) and 20 ul master plate soln. • Cannot perform fluorescence readings due to lack of calibration curves • Possible sources of error • Since not soluble in PBS drug release study may be fallible • Reuse of 96 well plates

  7. Solvent Solubility Tests • Qualitative testing using: • 0.2 g PCL (in 2 ml) overnight • 5 mg drug (in 1 ml) with and without heat

  8. The Solution • Tests were performed for 0.4 g PCL and 0.3+0.1 g PLGA+PCL in DMSO and DMF in preparation for a possible «Plan B» for casting • Vials were left stirring overnight, with some immediately encouraging results • DMF dissolved PCL at 50oC, while DMSO-PCL only melted to the side of the vial

  9. Friday, July 6th @ 2pm • Went to Communicable Disease Center 1 and met with Dr. RupeshAgrawal • Watched him perform routine follow up eye examinations • Took pictures of HIV patients for a new study he is working on • Watched 2 patients receive ocular injection • Patients receive 8 doses of 2000ug for 4 weeks and 4 doses of 1000ug the next 4 weeks • Drug is suspended in saline solution

  10. Next Steps • Continue release studies of both FDA, Ganciclovir & Valganciclovir • Find a solvent to dissolve Gan and PCL • Can make better films for both Ganciclovir & Valganciclovir • Complete calibration curves for both drugs • Use curves to find the best gains for drug release study to be read at

More Related